Our study provides additional information about statin intolerance epidemiology and indicated that new lipid‐lowering agents, such as PCSK9 inhibitors, may be an ideal option for older patients with AMI, especially those with liver dysfunction. The gene discussed is PCSK9; the disease is Decreased liver function.